Cannabis Science Inc (OTCMKTS:CBIS) Poised for Expansion in 2018


It was about a month ago that we last touched upon Cannabis Science Inc (OTCMKTS:CBIS) here on Street Register, and during that time, we witnessed an incredible run on the chart from .0483 to .1397 (+189.2%).


There has also been a lot happening with the company, given California’s recent high visibility in the cannabis market with the advent of legal sales. He company provided a significant update relating to tht story that we wanted to pass along to our readers today.

Cannabis Science Inc (OTCMKTS:CBIS) is preparing for the Grand Opening of its first two Pre ICO Pharmacies in California. These pharmacies will be managed through the use of a Pharmacy Automation and Inventory Tracking System.


“Cannabis Science’s Pharmacies are in prime, high traffic areas on Pico Boulevard in Los Angeles and on Ventura Boulevard in the San Fernando Valley. The Company has also been presented with an opportunity to purchase a potentially 60,000 sq. ft. building in Los Angeles, CA. This is where the Company can build its first Cannabis Science Medical Center, including full laboratory facilities, patient intake, and doctor and nurse clinics. We will look at the possible use of the Company’s rare U.S. Federal Government Cage Code Clearance to provide U.S. Federal Government approved Emergency Medical Services,” stated Mr. Raymond C. Dabney, Cannabis Science’s President, CEO, and Co-founder.


 “Our Pharmacies are designed to be state of the art facilities and they will be beautiful. We will showcase the entire Cannabis Science product line, as well as additional products from select vendors that meet the high standards that we have set for our CBIS-branded products,” continued Mr. Dabney. “As part of the Company’s overall drug-development strategy, the Cannabis Science Pharmacies will provide our Company with an important retail sales channel and allow us to interact directly with those who will benefit from our medicines – our patients.”


These new acquisitions offer Cannabis Science a very strong foothold in the medical services industry. In addition, the Company is actively negotiating with its East Coast Associates in Washington, D.C and New York City to expand the CBIS-branded Pharmacies into those areas and expect to announce our progress in the coming months.


The Company launched the Cannabis Science Global Consortium in 2017. This Consortium provides a framework to cooperate and collaborate with stakeholders worldwide. “The Cannabis Science Global Consortium links universities, foundations, corporations, and individuals to share research, ideas, and other relevant information, as well as to implement a cutting-edge research program to develop medicines and delivery mechanisms from bench-to-bedside,” stated Dr. Allen Herman, Cannabis Science’s Chief Medical Officer.


In 2017, Cannabis Science successfully registered to apply for U.S. Federal Government contracts and grants. As part of this registration process, the Company secured its Federal Commercial and Government Entity (CAGE) Code, which is issued by the Department of Defense’s (DoD) Defense Logistics Agency (DLA) CAGE Code Program Office. Cannabis Science is one of the only companies in its industry with the ability to receive U.S. Federal Government contracts and grants. Cannabis Science will use its expertise and relationships with Government Agencies and University Medical Research Groups to further Cannabinoid Pharmaceutical Development, and to reconfigure access to treatment with cannabinoids by designing and building effective and efficient pharmacies and medical clinics staffed by skilled health professionals. (Source: Globe Newswire)


In terms of domestic cannabis companies, CBIS is one of the big boys on the block, and it certainly seems as if the company is setting up for a big 2018. We’ll be sure to follow along closely and stay up on the company’s progress. Keep it locked on Street Register for updates, and we’ll deliver important developments on CBIS as they unfold. In the meantime, if you’ve yet to sign up for our 100% free newsletter, do so now! Just enter your active email address into the box below and submit!


Disclosure: No one at Street Register has been compensated in any way for the publishing of this article, nor do we hold any position in CBIS stock, short or long.